-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
NexImmune, Inc. (NASDAQ:NEXI) Sees Significant Increase in Short Interest
NexImmune, Inc. (NASDAQ:NEXI) Sees Significant Increase in Short Interest
NexImmune, Inc. (NASDAQ:NEXI – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 538,500 shares, a growth of 13.2% from the August 15th total of 475,800 shares. Currently, 3.6% of the company's stock are sold short. Based on an average trading volume of 1,620,000 shares, the days-to-cover ratio is presently 0.3 days.
NexImmune Stock Down 16.3 %
Shares of NASDAQ NEXI opened at $0.66 on Friday. NexImmune has a 52 week low of $0.66 and a 52 week high of $18.78. The business's 50 day moving average price is $1.23 and its 200 day moving average price is $2.02. The firm has a market cap of $15.88 million, a P/E ratio of -0.25 and a beta of 1.08.
Get NexImmune alerts:NexImmune (NASDAQ:NEXI – Get Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.03). As a group, research analysts expect that NexImmune will post -2.59 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. Barclays dropped their price objective on NexImmune from $7.00 to $2.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 16th. Raymond James cut their price objective on shares of NexImmune from $12.00 to $3.00 and set an "outperform" rating on the stock in a report on Tuesday, August 16th. Cantor Fitzgerald reiterated an "overweight" rating on shares of NexImmune in a research note on Wednesday, June 8th. Finally, BTIG Research initiated coverage on shares of NexImmune in a research note on Wednesday, June 1st. They set a "buy" rating and a $5.00 price objective for the company.Institutional Investors Weigh In On NexImmune
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kettle Hill Capital Management LLC purchased a new stake in shares of NexImmune in the second quarter worth about $439,000. State Street Corp boosted its position in NexImmune by 9.6% in the 1st quarter. State Street Corp now owns 214,018 shares of the company's stock worth $901,000 after purchasing an additional 18,730 shares in the last quarter. EPIQ Capital Group LLC acquired a new stake in shares of NexImmune during the 1st quarter worth approximately $802,000. Millennium Management LLC purchased a new position in shares of NexImmune during the 2nd quarter valued at approximately $292,000. Finally, Brown Brothers Harriman & Co. purchased a new position in shares of NexImmune during the 1st quarter valued at approximately $517,000. 34.45% of the stock is owned by institutional investors and hedge funds.
About NexImmune
(Get Rating)
NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
Featured Stories
- Get a free copy of the StockNews.com research report on NexImmune (NEXI)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.
NexImmune, Inc. (NASDAQ:NEXI – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 538,500 shares, a growth of 13.2% from the August 15th total of 475,800 shares. Currently, 3.6% of the company's stock are sold short. Based on an average trading volume of 1,620,000 shares, the days-to-cover ratio is presently 0.3 days.
新免疫公司(纳斯达克代码：NEXI-GET评级)是空头股数8月份大幅增长的目标。截至8月31日，空头股数共有538,500股，较8月15日的475,800股增长13.2%。目前，该公司3.6%的股票被卖空。以1，62万股的平均成交量计算，目前的天数与回补比率为0.3天。
NexImmune Stock Down 16.3 %
NexImmune股价下跌16.3%
Shares of NASDAQ NEXI opened at $0.66 on Friday. NexImmune has a 52 week low of $0.66 and a 52 week high of $18.78. The business's 50 day moving average price is $1.23 and its 200 day moving average price is $2.02. The firm has a market cap of $15.88 million, a P/E ratio of -0.25 and a beta of 1.08.
上周五，新浪纳斯达克的股价开盘报0.66美元。NexImmune的52周低点为0.66美元，52周高位为18.78美元。该业务的50日移动均线价格为1.23美元，其200日移动均线价格为2.02美元。该公司市值为1588万美元，市盈率为-0.25，贝塔系数为1.08。
NexImmune (NASDAQ:NEXI – Get Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.03). As a group, research analysts expect that NexImmune will post -2.59 earnings per share for the current year.
纳斯达克(股价代码：NEXI-GET Rating)最近一次发布季度收益数据是在8月15日星期一。该公司公布了该季度每股收益(0.69美元)，低于普遍预期的(0.66美元)和(0.03美元)。研究分析师预计，作为一个整体，NexImmune本年度的每股收益将达到2.59美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Institutional Investors Weigh In On NexImmune
机构投资者对NexImmune的看法
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kettle Hill Capital Management LLC purchased a new stake in shares of NexImmune in the second quarter worth about $439,000. State Street Corp boosted its position in NexImmune by 9.6% in the 1st quarter. State Street Corp now owns 214,018 shares of the company's stock worth $901,000 after purchasing an additional 18,730 shares in the last quarter. EPIQ Capital Group LLC acquired a new stake in shares of NexImmune during the 1st quarter worth approximately $802,000. Millennium Management LLC purchased a new position in shares of NexImmune during the 2nd quarter valued at approximately $292,000. Finally, Brown Brothers Harriman & Co. purchased a new position in shares of NexImmune during the 1st quarter valued at approximately $517,000. 34.45% of the stock is owned by institutional investors and hedge funds.
对冲基金和其他机构投资者最近增持或减持了该股。Kettle Hill Capital Management LLC在第二季度购买了价值约43.9万美元的NexImmune新股。道富集团在第一季度将其在NexImmune的头寸增加了9.6%。道富银行目前持有214,018股该公司股票，价值901,000美元，此前该公司在上个季度又购买了18,730股。Epiq Capital Group LLC在第一季度收购了价值约802,000美元的NexImmune新股。千禧管理公司在第二季度购买了价值约292,000美元的NexImmune股票的新头寸。最后，布朗兄弟哈里曼公司在第一季度购买了价值约51.7万美元的NexImmune新股票头寸。34.45%的股票由机构投资者和对冲基金持有。
About NexImmune
关于NexImmune
(Get Rating)
(获取评级)
NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
NexImmune，Inc.是一家临床阶段的生物技术公司，致力于开发对癌症和其他危及生命的免疫介导性疾病患者具有治愈潜力的疗法。它开发了基于其专利的人工免疫调制的T细胞免疫疗法的方法，这是一个纳米颗粒技术平台。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on NexImmune (NEXI)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- 免费获取StockNews.com关于NexImmune的研究报告(NEXI)
- 第四季度值得考虑的3家银行
- 股市：红海中的三座强国
- 有什么办法可以治愈Teladoc股票的问题吗？
- MarketBeat：回顾一周9/12-9/16
- 没有人告诉这三只股票这是下跌的一周
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.
接受NexImmune日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收关于NexImmune和相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧